Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Receives $36.60 Consensus Target Price from Brokerages

Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) has earned an average rating of “Buy” from the five brokerages that are covering the stock, Marketbeat reports. Five research analysts have rated the stock with a buy rating. The average twelve-month price objective among brokers that have covered the stock in the last year is $36.60.

Several research analysts have recently weighed in on the stock. JPMorgan Chase & Co. upped their target price on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI increased their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. Finally, Wedbush reiterated an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a research note on Monday, January 13th.

Insider Buying and Selling at Kiniksa Pharmaceuticals

In other Kiniksa Pharmaceuticals news, COO Eben Tessari sold 14,000 shares of the stock in a transaction on Monday, January 13th. The shares were sold at an average price of $18.24, for a total transaction of $255,360.00. Following the transaction, the chief operating officer now directly owns 88,975 shares in the company, valued at $1,622,904. This represents a 13.60 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Mark Ragosa sold 8,969 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the transaction, the chief financial officer now owns 22,958 shares in the company, valued at approximately $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock worth $745,589 in the last ninety days. 54.57% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth about $50,000. CWM LLC lifted its position in shares of Kiniksa Pharmaceuticals by 443.0% in the 3rd quarter. CWM LLC now owns 2,449 shares of the company’s stock worth $61,000 after buying an additional 1,998 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth about $80,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Kiniksa Pharmaceuticals in the 3rd quarter worth about $189,000. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Kiniksa Pharmaceuticals by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 7,810 shares of the company’s stock worth $195,000 after buying an additional 3,076 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Kiniksa Pharmaceuticals Trading Down 2.1 %

Shares of KNSA stock opened at $19.28 on Monday. The company has a market capitalization of $1.39 billion, a PE ratio of -137.70 and a beta of 0.32. The firm has a fifty day simple moving average of $19.88 and a 200-day simple moving average of $22.96. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.